KRAS G12C-IN-77
KRAS G12C-IN-77 is an orally active and selective KRASG12C covalent dual-state inhibitor that binds with high affinity to both GDP-bound (inactive state) and GTP-bound (active state) KRASG12C (IC50 = 133 nM). KRAS G12C-IN-77 rapidly inhibits ERK1/2 phosphorylation, induces the formation of covalent adducts with endogenous KRASG12C, suppresses the expression of MAPK pathway genes, and inhibits the proliferation of KRASG12C-mutant cells. KRAS G12C-IN-77 is applicable to research related to KRASG12C-mutant solid tumors, including pancreatic ductal adenocarcinoma and non-small cell lung cancer.
For research use only. We do not sell to patients.
- CAS No.: 3023465-19-9
- Formula: C39H34F3N7O2
- Molecular Weight:689.73
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
KRAS G12C-IN-77 (Compound 8) shows IC50 values <10 nM for G12C mutant cells and IC50 values >1000 nM for non-G12C mutant cells[1].
KRAS G12C-IN-77 inhibits phosphorylation of ERK1/2 in MIA PaCa-2 KRASG12C mutant cells with an IC50 of 0.4 nM[1].
KRAS G12C-IN-77 (5 days) potently inhibits proliferation of MIA PaCa-2 KRASG12C mutant cells with an IC50 of 1.6 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
KRAS G12C-IN-77 (150 mg/kg; p.o.; twice daily; 21 days) induces 88% tumor growth inhibition with robust target engagement and pathway suppression in the LUN-055 KRASG12C xenograft model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Crl:NU(NCr)-Foxn1^nu homozygous nude mice (female, 6-8 weeks old, implanted with MIA PaCa-2 KRAS G12C mutant cells)[1]
-
Dosage:5, 15, 50, 150 mg/kg
-
Administration:p.o.; single dose; daily; 21 days
-
Result:Achieved over 85% KRAS G12C covalent engagement and approximately 50% pERK suppression at 1 hour post 50 mg/kg and 150 mg/kg single dose relative to vehicle.
Reached maximum target engagement (over 90% at 150 mg/kg) with sustained pERK suppression by 7 hours post all single doses.
Induced significant tumor growth inhibition at 15 mg/kg, 50 mg/kg, and 150 mg/kg after 21 days of daily dosing.
Drove complete tumor responses in 6 of 8 animals (75%) with tumor volumes remaining near baseline at 150 mg/kg daily dose for 21 days.
-
Animal Model:BALB/c nude mice (female, 6-8 weeks old, implanted with LUN-055 KRAS G12C mutant tumor fragments)[1]
-
Dosage:150 mg/kg
-
Administration:p.o.; twice daily; 21 days
-
Result:Achieved 88% tumor growth inhibition relative to vehicle.
Reached high levels of KRAS G12C target engagement and significant pERK suppression measured 7 hours after the final dose.
Chemical Information
-
CAS No. 3023465-19-9
-
Molecular Weight 689.73
-
Formula C39H34F3N7O2
-
SMILES
[H]C#CC1=CC=CC2=CC=CC(C3=C(C4=C(C(N5CCN(CC5)C(/C(F)=C/C6=NC=CC=C6)=O)=NC(OC[C@@]78CCCN7C[C@@H](C8)F)=N4)C=N3)F)=C12
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
KRAS G12C-IN-77 Related Classifications
HY-181964 Related Classifications
Powered by Bioz